Compare Eli Lilly And Co (LLY) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Realty Income Corp — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Realty Income Corp trades at $54.18 (market cap $51.26B). The key difference: Eli Lilly And Co is far larger — about 20.3× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Realty Income Corp for 127 Days on average.
| LLY | O | |
|---|---|---|
Market Cap | $1.04T | $51.26B |
Volume | 3,064,878 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $1.28K | $67.56 |
52-Week Low | $799.57 | $53.35 |
Typical Hold Time | 93 Days | 127 Days |
Enterprise Value | $1.09T | $81.88B |
Dividend Yield | 0.59% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Realty Income (O) trades at $54.17, up 1.54% with a bearish technical signal despite recent dividend payments. The REIT shows strong fundamentals with 92.56% gross margins and 21.23% net income margin, though earnings have missed expectations for three consecutive quarters. Revenue growth continues from $5.3B in 2024 to $5.7B in 2025, while debt-to-asset ratio has increased to 39.93%.
Analysts maintain a cautious outlook with 38% buy ratings and $64.80 consensus target, representing 20% upside potential. Key risks include rising interest rates impacting REIT valuations and consecutive earnings misses. The stock offers income appeal with consistent dividends but faces headwinds from bond yield competition and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
